Seeking Alpha

Chelsea Therapeutics (CHTP) -24.1% premarket after announcing a clinical study of its...

Chelsea Therapeutics (CHTP) -24.1% premarket after announcing a clinical study of its investigational rheumatoid arthritis treatment CH-4051 missed a primary endpoint, and the drug maker says it has no further plans to develop the medication.
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs